NCT00347958已完成4 期
Safety Among Adolescents and Adults of Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®) 4 to 5 Years After a Previous Dose
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 545
- 试验地点
- 10
- 主要终点
- Percentage of Participants With at Least 1 Solicited Injection Site and Systemic Reactions Post-Vaccination
研究概览
简要总结
Objectives:
To provide safety data on revaccination with ADACEL® vaccine.
To describe the immune response to tetanus, diphtheria, and pertussis antigens following revaccination with ADACEL® vaccine 4-5 years after first vaccination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 15 Years 至 69 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Previously received ADACEL vaccine as part of Aventis Pasteur studies Td501, Td502, or Td
- •At least 15 but no greater than 69 years of age at the time of vaccination in this trial.
- •Signed Institutional Review Board (IRB)-approved informed assent / consent form.
- •Able to attend all scheduled visits and to comply with all trial procedures.
- •For a woman, inability to become pregnant or negative serum/urine pregnancy test.
排除标准
- •Any condition which, in the opinion of the investigator, would pose a health risk to the participant or interfere with the evaluation of the vaccine.
- •Serious chronic disease (ie, cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric) that is unstable or that might:
- •interfere with the ability to participate fully in the study; or
- •interfere with evaluation of the vaccine.
- •Known or suspected impairment of immunologic function.
- •Febrile illness within the last 72 hours or an oral temperature ≥100.4°F (≥38°C) at the time of inclusion.
- •History of documented tetanus, diphtheria or pertussis disease within the preceding 5 years.
- •Known or suspected receipt of a tetanus-, diphtheria- or pertussis-containing vaccine since participation in Study Td501, Td502, or Td
- •(Receipt of Menactra vaccine at any time prior to the present study is permitted, subject to the next exclusion criterion).
- •Received any vaccine, other than influenza vaccine, in the 28-day period prior to enrollment or scheduled to receive any vaccine, other than influenza vaccine, in the 28-day period after enrollment. For influenza vaccine only, defer if received in the 14-day period prior to enrollment or scheduled to receive in the 14-day period after enrollment
- •Administration of immune globulin or other blood products within the last three months, or injected or oral corticosteroids or other immunomodulator therapy within six weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting less than 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment.
- •Suspected or known hypersensitivity to any of the vaccine components or to latex.
- •Unable to attend the scheduled visits or to comply with the study procedures.
- •In females of childbearing potential, a positive or equivocal urine pregnancy test at enrollment.
- •Nursing mother.
- •Participation in another interventional clinical trial in the 4 weeks preceding enrollment or planning to participate in another interventional clinical trial during the planned period of this study.
- •Current abuse of alcohol or drug addiction that may interfere with the subject's ability to comply with trial visits or procedures.
- •Thrombocytopenia or bleeding disorder contraindicating intramuscular (IM) vaccination.
- •Subject deprived of freedom by an administrative or court order, or under the stress of an emergency setting, or hospitalized without his/her consent.
结局指标
主要结局
Percentage of Participants With at Least 1 Solicited Injection Site and Systemic Reactions Post-Vaccination
时间窗: 0-14 days post-vaccination
Solicited Injection Site Reactions: Pain, Erythema/Redness, Swelling. Solicited Systemic Reactions: Fever (Temperature), Headache, Myalgia, Malaise.
次要结局
未报告次要终点
研究者
研究点 (10)
Loading locations...
相似试验
已完成
3 期
A Study to Assess the Safety of Adacel® VaccineDiphtheriaTetanusPertussisNCT01040052Sanofi Pasteur, a Sanofi Company30
已完成
4 期
Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous DosePertussisWhooping CoughTetanusDiphtheriaNCT01439165Sanofi Pasteur, a Sanofi Company1,330
已完成
4 期
Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™PolioHaemophilus InfectionTetanusPertussisDiphtheriaNCT00802867Sanofi Pasteur, a Sanofi Company989
已完成
1 期
Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in ChinaDiphtheriaPertussisTetanusNCT01933776Sanofi Pasteur, a Sanofi Company40
已完成
3 期
Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®DiphtheriaTetanusPertussisNCT00258895Sanofi Pasteur, a Sanofi Company649